Vistagen Therapeutics Announces Positive OLE Data from PALISADE-4 Phase 3

What Happened
Vistagen Therapeutics, Inc. filed a Form 8‑K on September 22, 2026 (Item 8.01) to announce preliminary positive results from the open‑label extension (OLE) portion of its PALISADE‑4 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. The company said OLE participants showed indications of improvement over time and reported safety observations supportive of prior fasedienol clinical data. Vistagen also said it plans to meet with the U.S. Food and Drug Administration (FDA) during the current quarter to discuss the regulatory path forward and potential New Drug Application (NDA) submission.

Key Details

• Filing date: September 22, 2026 (Form 8‑K, Item 8.01); press release attached as Exhibit 99.1.
• Study: PALISADE‑4 Phase 3 — announced preliminary positive findings from the open‑label extension (OLE) for fasedienol in acute social anxiety disorder.
• Clinical takeaways reported: indications of patient improvement over time in the OLE and safety data consistent with prior fasedienol studies.
• Next steps: Vistagen plans to meet with the FDA during the current quarter to discuss potential regulatory path and the possibility of supporting an NDA.

Why It Matters
Positive Phase 3 OLE data can strengthen Vistagen’s clinical case for fasedienol and inform discussions with the FDA about a potential NDA for the acute treatment of social anxiety disorder. For investors, the update is a development milestone in the drug’s regulatory timeline—but the company emphasizes these are preliminary findings and includes standard forward‑looking disclaimers and risk disclosures.